Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population
- PDF / 851,548 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 87 Downloads / 181 Views
ORIGINAL ARTICLE
Association Between Vedolizumab Levels, Anti‑vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases Andres J. Yarur1 · Parakkal Deepak2 · Niels Vande Casteele3 · Robert Battat4 · Anjali Jain5 · Lauren Okada5 · Mark Osterman6 · Miguel Regueiro7 Received: 12 September 2020 / Accepted: 8 October 2020 © The Author(s) 2020
Abstract Background The aim of this study was to assess the relationship between serum vedolizumab (VDZ) concentrations and antibodies to VDZ (ATV) in a large cohort of patients with inflammatory bowel diseases. Furthermore, we evaluated the association between serum VDZ concentrations and a novel serum-based biomarker panel designated as the endoscopic healing index (EHI), developed and validated for identifying mucosal inflammation in patients with Crohn’s disease (CD). Methods Retrospective study where results from patient samples submitted to a commercial clinical laboratory were included. Serum VDZ and ATV levels were analyzed using a drug-tolerant assay. In CD patients for whom both VDZ and EHI were available, VDZ concentrations were correlated with EHI. serum VDZ threshold analysis was performed using ROC curves, and the serum VDZ concentrations that best differentiated EHI
Data Loading...
